Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Polyethylene glycol for constipation

Polyethylene glycol for constipation S ir , We have read with interest the paper from Chaussade and Minic published in your journal on January 2003 ( APT 2003; 17: 165–172). The results clearly indicate that polyethylene glycol (PEG) based products are effective in chronic constipation, although some conclusions of the authors are irrelevant or misleading. In this randomized comparative study, two different doses of each PEG laxative (Transipeg and Forlax), were compared in four different arms. Transipeg 5.9 g, Forlax 10 g, Transipeg 11.5 g and Forlax 20 g, i.e. one or two sachets of each product daily. The primary end point was stool frequency; other symptoms of constipation were secondary end points. At week 4, all the doses were considered as equally effective as stool frequency and other symptoms of constipation did not differ significantly between the groups. The author concluded that on a per gram basis, Transipeg was more potent than Forlax. This conclusion is somewhat misleading. As Transipeg contains a significant amount of sodium sulphate (0.56 g/sachet), a very potent hyperosmotic laxative), in reality, it cannot be compared directly in terms of ‘potency’ to a sodium sulphate free compound such as Forlax. The conclusion that PEG 3350 is more http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Alimentary Pharmacology & Therapeutics Wiley

Polyethylene glycol for constipation

Halphen, Marc
Alimentary Pharmacology & Therapeutics , Volume 19 (10) – May 1, 2004
Download PDF
2 pages

Loading next page...
 
/lp/wiley/polyethylene-glycol-for-constipation-0x21pkvbvi

References (6)

Publisher
Wiley
Copyright
Copyright © 2004 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0269-2813
eISSN
1365-2036
DOI
10.1111/j.1365-2036.2004.01925.x
pmid
15142204
Publisher site
See Article on Publisher Site

Abstract

S ir , We have read with interest the paper from Chaussade and Minic published in your journal on January 2003 ( APT 2003; 17: 165–172). The results clearly indicate that polyethylene glycol (PEG) based products are effective in chronic constipation, although some conclusions of the authors are irrelevant or misleading. In this randomized comparative study, two different doses of each PEG laxative (Transipeg and Forlax), were compared in four different arms. Transipeg 5.9 g, Forlax 10 g, Transipeg 11.5 g and Forlax 20 g, i.e. one or two sachets of each product daily. The primary end point was stool frequency; other symptoms of constipation were secondary end points. At week 4, all the doses were considered as equally effective as stool frequency and other symptoms of constipation did not differ significantly between the groups. The author concluded that on a per gram basis, Transipeg was more potent than Forlax. This conclusion is somewhat misleading. As Transipeg contains a significant amount of sodium sulphate (0.56 g/sachet), a very potent hyperosmotic laxative), in reality, it cannot be compared directly in terms of ‘potency’ to a sodium sulphate free compound such as Forlax. The conclusion that PEG 3350 is more

Journal

Alimentary Pharmacology & Therapeutics – Wiley

Published: May 1, 2004

There are no references for this article.